177Lu-LNC1004
Solid Tumor, Unspecified, Adult
Yantai LNC Biotechnology Singapore PTE. LTD.radiopharmaceuticalPhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
12 Active assets in the Solid Tumor, Unspecified, Adult cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
rc48-adc Hutchmed | Phase 1/2 | CCC |
ad1208 Avelos Therapeutics Inc. | Phase 1/2 | CCC |
Fruquintinib Hutchmed | Phase 1/2 | CCC |
Tislelizumab Hutchmed | Phase 1/2 | CCC |
Pyrotinib Hutchmed | Phase 1/2 | CCC |
View all 18 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →